Retatrutide counteracts liver impairment in high- fat/sucrose diet induced obesity in male rats

Abstract

Background: Obesity constitutes a major worldwide public health crisis in the 21st century, with its prevalence increasing annually in both industrialized and developing countries. Obesity, a multifactorial illness marked by excessive adiposity, is closely associated with several; metabolic, hepatic, and Non-alcoholic fatty liver disease (NAFLD) is prominent contributors to chronic illness and premature mortality. Dietary fat consumption is frequently attributed to the rise in adiposity.  studies have demonstrated that high-fat diets (30% of energy derived from fat) can readily produce obesity. This study investigates the retatrutide effects on weight loss, blood glucose, and liver enzymes, aiming to explore its potential as a protect the liver.

Methode: A total of 28 adult males Sprague-Dawley rats were utilized and categorized into four groups; the control group consisted of seven rats on a standard diet for 12 weeks, whilst the remaining rats were administered a high-fat/sucrose diet. Obese rats were divided into three groups after eight weeks on a high-fat/sucrose diet: obesity, Retatrutide (25 nmol/kg) subcutaneously, and vehicle (D.W.) groups, and treated for four weeks. Information pertaining to body weight, blood glucose, serum insulin concentrations, and hepatic enzymes.

Results: results revealed that Retatrutide-treated obese rats exhibited significantly reduced body weight, blood glucose, serum insulin, and AST levels compared to obese untreated rats.

Conclusions: It concluded that Retatrutide treatment mitigates the metabolic dysregulations induced by high fat /sucrose diet, additionally; it ameliorates liver impairment.